February 11, 2019
NRG Oncology Broadcast archives are accessible from our website at any time. Please bookmark  this link  for your convenience.

 
Our NRG Oncology Semiannual Meeting was hosted last week with our largest attendance of all time. During this meeting, we celebrated NRG Oncology’s 5th birthday as an organization. More information and communications to follow.

 

OTHER PROTOCOL NOTICES

1. Children’s Oncology Group Protocol AGCT1531: “A Phase III Trial of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors” is open to patient entry. It is available on the CTSU menu with Dr. Allan Covens as NRG Champion. Please enroll your eligible patients to this important trial.

Enrollment credited to NRG Oncology will count towards membership requirements.

 

2. GYNECOLOGIC

NRG-GY004 Data Freeze - March 2019

NRG-GY004 is maturing for the final analysis. Please ensure all data is up to date (including follow-up information), and all queries are answered. We expect to start the final analysis in March 2019.  We will provide the results of this important study to you as soon as possible. If you have any questions please contact Sandy Dascomb at [ DascombS@NRGOncology.org].

 

Form TR for Biospecimens Shipped to NRG Biospecimen Bank-Columbus

Please note that the NRG Patient ID (e.g., AB###-GY###-#####) must be included on any copies of Form TR shipped to the NRG Biospecimen Bank-Columbus. If the NRG Patient ID does not appear on the top, left of Form TR, please hand-complete the NRG Patient ID before sending the form to the NRG Biospecimen Bank-Columbus. Do not complete the NRG Patient ID for forms accompanying biospecimens shipped to laboratories other than the NRG Biospecimen Bank-Columbus. Please contact the NRG Biospecimen Bank-Columbus at bpcbank@nationwidechildrens.org  if you need assistance or have additional questions.

 

Biospecimen Bank-Columbus & SDMC Undergoing Refurbishment

Please be advised that the data exchange between the Biospecimen Bank-Columbus and SDMC is undergoing refurbishment. During this time, biospecimen receipt information will not appear in Rave or SEDES. Biospecimen transmittal forms (i.e., Form SP and Form TR) will ultimately not appear as overdue during this time; however, there may be a brief period over the next several weeks during which forms may temporarily appear as overdue. If this should occur or if you experience any other issues, please notify Support at support@nrgoncology.org. Sites should continue to return inquiries from Biospecimen Bank-Columbus staff regarding biospecimen receipt during this time.

 

3. VTOC TRAINING

The VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on RTOG 0924, RTOG 0920, NRG-HN001, NRG-HN002, NRG-CC003 and NRG-CC004. Space is limited so register now to reserve your seat. The next training is scheduled for March 13, 2019.

 

DRUG SAFETY UPDATES AND INVESTIGATOR’S BROCHURE (IB) NOTICES

 

Safety updates have been issued for the following studies:

DRUG NAME

PROTOCOL

WEBSITE FOR SAFETY REPORTS

INVESTIGATOR'S BROCHURE (IB)*

Atezolimumab

NRG-GI004

NRG-GY009

NRG-GY017

CTSU

CTSU

NRG

 

Epacadostat

NRG-GY016

CTSU

X

Ipilimumab

NRG-BN002

NRG-GY003

NRG

NRG

 

Nivolumab

NRG-BN002

NRG-GY003

NRG

NRG

 

Olaparib

NRG-GY004

NRG-GY005

NRG-GY012

NSABP B-55

CTSU

CTSU

CTSU

CTSU

X

X

X

Pembrolizumab

NRG-GI002

NRG-GY016

NRG-HN003

CTSU

CTSU

NRG

 


*The current version of the Investigator Brochure Documents for Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI)-sponsored trials are available for access via the Cancer Therapy Evaluation Program (CTEP) Online Agent Order Processing (OAOP) website ( https://ctepcore.nci.nih.gov/OAOP/. Log-in using your Identity and Access Management (IAM) username and password credentials and provide the requested information to access the document.


Every site principal investigator is responsible for reviewing this document. The Investigator Brochure is for use by the site principal investigator and any study personnel under his/her supervision who need to know the contents for the conduct of a clinical trial, including Institutional Review Board(s) or Independent Ethics Committee(s).

NRG Oncology is pleased to report the scientific articles and abstracts that have appeared or have been presented during the previous week. This publications report includes links, when available, to the article, PubMed abstract, or association abstract.

 

JOURNAL ARTICLES

Barboriak DP, Zhang Z, Desai P, Snyder BS, Safriel Y, McKinstry RC, Bokstein F, Sorensen G, Gilbert MR, Boxerman JL. Interreader Variability of Dynamic Contrast-enhanced MRI of Recurrent Glioblastoma: The Multicenter ACRIN 6677/RTOG 0625 Study. Radiology. 2019 Feb;290(2):467-476.  Read more

 

Crook JM, Zhang P, Pisansky TM, Trabulsi EJ, Amin MB, Bice W, Morton G, Pervez N, Vigneault E, Catton C, Michalski J, Roach M 3rd, Beyer D, Jani A, Horwitz E, Donavanik V, Sandler H. A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526). Int J Radiat Oncol Biol Phys. 2019 Feb 1;103(2):335-343.  Read more

 

Nie K, Al-Hallaq H, Li XA, Benedict SH, Sohn JW, Moran JM, Fan Y, Huang M,Knopp MV, Michalski JM, Monroe J, Obcemea C, Tsien CI, Solberg T, Wu J, Xia P,Xiao Y, El Naqa I. NCTN Assessment on Current Applications of Radiomics in Oncology. Int J Radiat Oncol Biol Phys. 2019 Jan 31. pii: S0360-3016(19)30178-6. doi: 10.1016/j.ijrobp.2019.01.087. [Epub ahead of print] Review. PubMed PMID: 30711529.  Read more

 

Saad ED, Squifflet P, Burzykowski T, Quinaux E, Delaloge S, Mavroudis D, Perez E, Piccart-Gebhart M, Schneider BP, Slamon D, Wolmark N, Buyse M.  Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. Lancet Oncol. 2019 Jan 29. pii: S1470-2045(18)30750-2. doi: 10.1016/S1470-2045(18)30750-2. [Epub ahead of print] PubMed PMID: 30709633  Read more

 

PUBLICATIONS REMINDERS

Please note the following upcoming meeting and abstract submission deadline dates

 

Upcoming Meetings

American Association for Cancer Research (AACR); Mar 29 - Apr 3, 2019; Atlanta, GA

American Society of Clinical Oncology (ASCO) GU; Feb 14-16, 2019; San Francisco, CA


Society of Gynecologic Oncology (SGO)
; Mar 16-19, 2019; Honolulu, HI


Society of Surgical Oncology (SSO)
; Mar 27-30, 2019 ; San Diego, CA


St. Gallen Breast Cancer Conference (SG-BCC);
Mar 20-23, 2019; Vienna, Austria

 

Upcoming Abstract Submission Deadlines

 

American Association of Physicists in Medicine (AAPM); Jul 14-18, 2019; San Antonio, TX; due to publications committee Feb 21, 2019; meeting submission deadline Mar 7, 2019

American Society of Clinical Oncology (ASCO); May 31 - Jun 4, 2019; Chicago, IL; meeting submission deadline Feb 12, 2019; LBA Mar14, 2019 noon ET

American Society for Radiation Oncology (ASTRO); Sep 15-18, 2019; Chicago, IL; meeting submission deadline Feb 24, 2019

ESMO Breast Cancer Annual Congress; May 2-4, 2019; Berlin, Germany; LBA deadline Apr 1, 2019 noon CEST (Central European Summer Time)

International Society for Quality of Life Research (ISOQOL); Oct 20-23, 2019; San Diego, CA; due to publications committee Mar 26 2019; meeting submission deadline Apr 8, 2019

 

NRG Oncology is proud to be an active participant of #CancerMoonShot.
This message was sent from NRG-Broadcasts@NRGOncology.org to NRG-Broadcasts@NRGOncology.org
Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Update Profile/Email Address | Forward Email | Report Abuse